Real-world evaluation of the efficacy and safety of disitamab vedotin (RC48) in urothelial carcinoma

RC48 showed encouraging activity and manageable safety in a real-world UC cohort. Prospective multicenter studies with longer follow-up are needed to validate these findings, compare monotherapy versus combination strategies, and define the optimal role of RC48 across UC disease stages.

Authors

Institutions

Publication Details

Journal
BMC Urology
Published
2025-11-05
DOI
https://doi.org/10.1186/s12894-025-01960-y
Citations
2
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
4.01
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-world evaluation of the efficacy and safety of disitamab vedotin (RC48) in urothelial carcinoma

Haojie Liu, Sihai Shao, Yuefan Shen, Tianxiang Zhou
2 citations
BMC Urology
Bladder and Urothelial Cancer Treatments
4.01
article

Real-world evaluation of the efficacy and safety of disitamab vedotin (RC48) in urothelial carcinoma

Haojie Liu, Sihai Shao, Yuefan Shen, Tianxiang Zhou
article en
2 citations

Abstract

RC48 showed encouraging activity and manageable safety in a real-world UC cohort. Prospective multicenter studies with longer follow-up are needed to validate these findings, compare monotherapy versus combination strategies, and define the optimal role of RC48 across UC disease stages.

BMC UrologyVol. 25(1)
Huzhou Normal University (CN)
Openalex Percentile: Top 6%
Bladder and Urothelial Cancer Treatments
4.01
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Real-world evaluation of the efficacy and safety of disitamab vedotin (RC48) in urothelial carcinoma — Haojie Liu, Sihai Shao, et al. · BMC Urology (2025) | TGRS Research Map | TGRS